LRIG New England Chapter
Automated Cell Culture
|
Sponsored by:
|
|
AGENDA:
| 6:15pm |
Seth Rogers,
BioProcessors Corporation High Throughput Experimentation as an Enabling Technology for Bioprocess Development <download presentation> |
| 6:50pm |
Chris Hogan,
Novartis Institutes for Biomedical
Research Novartis - Of cells and Automation: A Perspective on Harnessing Cell Dynamics in the Automated HTS Environment <download presentation> |
| 7:25pm |
Brad A. Justice,
Global Cell Solutions Inc. Fully Automated 3D Cell Culture: Leveraging Relevant and Consistent Drug Discovery <download presentation> |
Abstracts & Bios:
Chris Hogan, Novartis Institutes for Biomedical Research
Biography
Chris Hogan is a Senior Technical Leader with the Novartis Institutes for Biomedical Research in Cambridge MA. Since 2003, he helped establish a cellular biology resources group centered around the TAP SelecT platform. His group supports all cellular screening, electrophysiology, and membrane needs for hit discovery and pre-clinical safety profiling at the Cambridge facility. Prior to Novartis, Chris worked in the Oncology department at Millennium Pharmaceuticals developing somatic cell knockout models and reporter cell lines for profiling novel protein functions. Chris will speak his thoughts on the peculiarities of living cells as discovery tools, and of the automated microcosm in which such cells are harnessed for downstream discovery efforts.
“Fully Automated 3D Cell Culture: Leveraging Relevant and Consistent Drug Discovery”
Brad A. Justice, Director of Research, Global Cell Solutions, Inc. 770 Harris Street, Suite 104, Charlottesville, VA 22903.
Biography
With a variety of research and entrepreneurial experiences, Mr. Justice possesses a wide scope of research and laboratory management expertise. Mr. Justice has created novel tools and methods to characterize and understand the action of popular antidepressants such as Prozac. Additional past projects include identifying genes relevant to Parkinson’s disease and characterization of the biological mechanisms that dictate cellular and structural polarities. At GCS, he supervises and executes all R&D activities and is responsible for developing the GEM™ technology. Furthermore, he is the Principal Investigator for a NSF grant award to commercialize cryopreserved cells as reagents.
"High Throughput Experimentation as an Enabling Technology for
Bioprocess Development
Seth
Rodgers CTO, BioProcessors Corporation
Bioprocess
development requires multi-factorial experimentation using
scale-down models at every step. However, traditional scale-down
models have limitations that frequently constrain the possible scope
and/or relevance of experimentation. In particular : bioreactor
experimentation is often prohibitively expensive, and simple models
such as well plates, tubes, and flasks do not often provide enough
insight to link manipulations of process parameters to changes in
process outcome. The SimCell system addresses this problem by
providing many of the measurements and controls commonly found in
bioreactors. It performs fed-batch protocols with pH, DO, and
glucose control across hundreds of micro-bioreactors. Offline
analytical systems can be used to obtain product quality information
from small micro-bioreactor samples in very high throughput,
permitting rapid evaluation of process design choices.
Informatics challenges arising from the need to integrate
many disparate data sets are also addressed. Finally, by combining
cell culture, analytics, and informatics, a workflow that represents
a 20 to 50 fold improvement in throughput over traditional methods
can be created.
Biography
Seth Rodgers
has served as CTO of BioProcessors since 2002, where he has led the
development of technologies for high throughput, multi-factorial
experimentation. Development activities have focused on creating a
micro-bioreactor array for use with high throughput automaton, and
have more recently been directed toward improving the accuracy of
micro-reactor systems as scale down models for larger scale
bioreactors. Deployment of process analytic technologies and
improved control strategies at the microscale is an area of
particular interest. Prior to BioProcessors, Seth was a consultant
with McKinsey and company in